       Document 0839
 DOCN  M9480839
 TI    Screening a low prevalence population for HIV-2 using a combination
       HIV-1/HIV-2 enzyme immunoassay and an immunofluorescence assay.
 DT    9410
 AU    Zanto SN; Treichel LJ; Abbott DO; Montana Public Health Laboratory,
       Helena.
 SO    Abstr Gen Meet Am Soc Microbiol. 1994;94:554 (abstract no. C-361).
       Unique Identifier : AIDSLINE ASM94/94313106
 AB    The Montana Public Health Laboratory has conducted screening for HIV-1
       since 1985, with an estimated prevalence of HIV infection of 0.06%. To
       evaluate test performance and to determine the feasibility of
       incorporating screening for HIV-2, 2000 random serum specimens received
       for routine screening were tested using both Genetic Systems HIV-1/HIV-2
       EIA and Viral Testing Systems Fluorognost HIV-2 IFA kits. Of the 2000
       specimens screened, 1949 specimens were negative in both the EIA and IFA
       test systems. Three specimens were repeatedly reactive by EIA, and
       negative by IFA. One specimen was positive in both the EIA and IFA test
       systems. Forty-seven (47) specimens were EIA non-reactive and IFA
       repeatedly indeterminate. In order to resolve HIV antibody status of the
       reactive serum specimens, additional testing was necessary on 4 of 2000
       EIA specimens, and 48 of 2000 IFA specimens. The present HIV-2 IFA kit
       appears better suited for supplemental HIV-2 testing rather than
       screening low prevalence populations. The incorporation of routine HIV-2
       screening into the HIV testing algorithms of low prevalence populations,
       although feasible, may not be an appropriate use of limited public
       health resources.
 DE    Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL  Comparative
       Study  Fluorescent Antibody Technique  Human  HIV Antibodies/*BLOOD  HIV
       Seronegativity  HIV Seropositivity  *HIV Seroprevalence  HIV-1/ISOLATION
       & PURIF  HIV-2/*ISOLATION & PURIF  Immunoenzyme Techniques  Mass
       Screening  Montana/EPIDEMIOLOGY  Random Allocation  Reagent Kits,
       Diagnostic  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

